Caica Digital (2315) · InitiativeRestated
Strengthening Product and System Development Through the Acquisition of Cryption’s OTC Derivatives Business
First written in FY2020-Q3. 1 of 2 entries say "Restated". Latest entry: FY2020.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Strengthening Product and System Development Capabilities Through the Acquisition of Cryption’s OTC Derivatives BusinessA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2020RestatedAnnual report
「Our consolidated subsidiary eワラント証券株式会社 acquired the OTC derivatives business from 株式会社Cryption on 1 May 2020.」
The measure to leverage synergies in new product design, system development and stable operation, and risk management through the acquisition of the OTC derivatives business was confirmed for the full fiscal year as well. - FY2020-Q3First statedAnnual report
「Our consolidated subsidiary eワラント証券株式会社 acquired the OTC derivatives business from 株式会社Cryption on 1 May 2020.」
On 1 May 2020, eワラント証券 acquired the OTC derivatives business, with synergies expected in new product design, system development and stable operation, and risk management. The acquisition cost was ¥30 million and goodwill of ¥27 million was recognised.